← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Savara, Inc.
Austin, TX
$4,510,349
Total funding
4
Grants
Funding over time
peak $1.7M · FY2011–15$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$4,510,349 · 4
By mechanism
R44$3,986,098 · 1
R43$333,898 · 2
U43$190,353 · 1
Investigators at Savara, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Development of Inhaled Vancomycin for Treatment of MRSA Infections in CF$1,680,649
R44 · FY2014 · HL
Development of Inhaled Vancomycin for Treatment of MRSA Infections in CF$1,290,369
R44 · FY2013 · HL
Development of Inhaled Vancomycin for Treatment of MRSA Infections in CF$1,015,080
R44 · FY2015 · HL
Targeted nanoparticle gene therapy for lung cancer$190,353
U43 · FY2013 · CA
A High Efficiency Corticosteroid Dry Powder Inhaler for Pediatric Use$184,148
R43 · FY2011 · AI
Development of Inhaled Vancomycin for Treatment of MRSA Infections in CF$149,750
R43 · FY2012 · HL